|
|
|
Congressional
Testimony
|
|
|
|
|
|
|
|
|
|
1998
October
- Dr. Michael A. Friedman,
October 7, 1998
Acting Commissioner, Food and Drug Administration, before
the Committee on Commerce to reconfirm the commitment of the
Food and Drug Administration (FDA or the Agency) to full and
timely implementation of the FDA Modernization Act of 1997
(FDAMA or the Act).
- Sharon Smith-Holston, October 2,
1998
Deputy Commissioner for External Affairs, Food and Drug Administration,
before the Committee on Commerce on Sector Annex for Pharmaceutical
Good Manufacturing Practices (the Annex) of the Agreement
on Mutual Recognition between the United States of America
and the European Community (MRA).
September
- William B. Schultz, September
24, 1998
Deputy Commissioner for Policy, Food and Drug Administration,
before the Committee on Government Affairs on safety of imported
foods.
- John Callan, Ph.D., September 24,
1998
Assistant Secretary for Management and Budget, and Chief Information
Officer (CIO) for the Department of Health and Human Services
(DHHS) before the Committee on Veterans' Affairs on information
on the Year 2000 date issue as it relates to medical devices.
- Dr. Michael A. Friedman,
September 9, 1998
Acting Commissioner of Food and Drug Administration, before
the Committee on Government Reform and Oversight on FDA's
regulatory compliance program which helps assure the safety
of blood and plasma derivatives through the application of
good manufacturing practices (GMP) as well as the continuing
shortage of immune globulin, intravenous (Human) (IGIV), the
subject of the subcommittee hearing on May 7 of this year.
July
- Dr. Michael A. Friedman, July 23,
1998
Acting Commissioner, Food and Drug Administration, before
the Special Committee on the Year 2000 Technology Problem
on the Year 2000 date issue as it relates to medical devices.
- Dr. Bruce Burlington, July 23,
1998
Director, Center for Devices and Radiological Health, Food
and Drug Administration, before the Subcomittee on Health
and the Environment on FDA's regulation of over-the-counter
(OTC) test systems for drugs of abuse.
May
- Dr. Bruce Burlington, May 8, 1998
Director, Center for Devices and Radiological Health, Food
and Drug Administration, before the Subcomittee on Health
and the Environment on the critical importance of safeguarding
womens health with Dr. Florence Houn, Director, of the Division
of Mammography Quality and Radiation Programs at CDRH.
- Michael A. Friedman, M.D., May
7, 1998
Lead Deputy Commissioner of Food and Drug Administration,
before the Committee on Government Reform and Oversight on
the shortage of immune globulin products and the efforts of
FDA to respond to the shortages.
- John Jenkins, M.D., May 6, 1998
Director, Division of Pulmonary Drug Products at the Center
for Drug Evaluation and Research (CDER), Food and Drug Administration,
before the Committee on Labor and Human Resources on the implementation
of Title VI of the Clean Air Act as it relates to the use
of chlorofluorocarbons (CFCs) in metered-dose inhalers (MDIs).
April
- Michael A. Friedman, M.D., April
30, 1998
Lead Deputy Commissioner of Food and Drug Administration,
before the Congressional Caucus for Women's Issues on our
cancer initiative, and some of the Agency's activities related
to women's health, such as women in clinical trials and our
Take Time To Care initiative.
- Michael A. Friedman, M.D., April
22, 1998
Lead Deputy Commissioner of Food and Drug Administration,
before the Committee on Government Reform and Oversight on
various programs for providing access to promising therapies
for seriously ill and dying patients.
- John Jenkins, M.D., April 2,
1998
Director of the Pulmonary Drug Products Division at the Center
for Drug Evaluation and Research (CDER), Food and Drug Administration,
before the Committee on Labor and Human Resources on the implementation
of Title VI of the Clean Air Act as it relates to the use
of chlorofluorocarbons (CFCs) in metered-dose inhalers (MDIs).
- Michael A. Friedman, M.D., April
1, 1998
Lead Deputy Commissioner of Food and Drug Administration,
(FDA or the Agency) management and procurement policies and
practices in general, and specifically as they relate to CBER.
March
- Randolph
F. Wykoff, M.D, March17, 1998
Associate Commissioner
for Operations, Food and Drug Administration before
the Committee on Veterans' Affairs to discuss the Agency's
role in the medical, chemical, and biological warfare preparedness
program of the Department of Defense (DOD).
February
- William B. Schultz, February 10,
1998
Deputy Commissioner for Policy, Food and Drug Administration,
before the Committee on Labor and Human Resources on proposals
for comprehensive tobacco legislation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|